Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER’s ‘Courageous’ Coronavirus Guidance Strategy May Catch-On

Executive Summary

Director Peter Marks says faster guidance development practices produced well-written documents and may be adopted once the pandemic ends.

You may also be interested in...



After Pandemic, US FDA Commissioner Wants To Continue ‘Rolling Review’ Offered To COVID-19 Products

Stephen Hahn also said the expedited approval process could be even more efficient.

US FDA Expects COVID-19 Vaccines To Meet ‘EUA Plus’ Standards, Marks Says

CBER director said that all the manufacturing data may not be available, but the safety and efficacy data needed for a BLA are expected before an emergency use authorization is granted.

Coronavirus Notebook: Emergency Use Authorization For Blood Plasma Therapy, Pandemic Workloads, US FDA Offices, Rx Mail Deliveries

US FDA issues controversial use emergency authorization for blood plasma therapy while agency officials note workloads nearly double under coronavirus treatment acceleration program. This and more in the Pink Sheet's latest coronavirus update.

Related Content

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel